Advocacy intelligence hub — real-time data for patient organizations
FIDAXOMICIN: FDA approved
INMAZEB®: FDA approved
treatment of infection caused by Zaire ebolavirus in adult and pediatric patients, including neonates born to a mother who is RT-PCR positive for Zaire ebolavirus infection
Dificid: FDA approved
DIFICID® is indicated in adult and pediatric patients aged 6 months and older for the treatment of C. difficile-associated diarrhea (CDAD).
Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.
FINANCIAL LANDSCAPE SUMMARY
Total programs
Open now
Copay cards
Copay Assistance1
Dificid
Cubist Pharmaceuticals LLC, a subsidiary of Merck Sharp & Dohme LLC
Dificid
(fidaxomicin)Orphan drugCubist Pharmaceuticals LLC, a subsidiary of Merck Sharp & Dohme LLC
Macrolide Antibacterial [EPC]
12.1 Mechanism of Action Fidaxomicin is an antibacterial drug [see Microbiology (12.4) ] .